Vor Biopharma Inc. Common StockVOR
Scheduled
Vor Biopharma Inc. Common Stock Citigroup’s Biopharma Back to School Summit 2026
Review the key takeaways and the transcript of this earnings call.
Period 2026
Key takeaways
- Vor Biopharma focuses on B cell mediated autoimmune diseases and licensed Telitasisept, a BAF April inhibitor, in June 2025.
- Telitasisept is approved in six indications in China and is being developed in the US and elsewhere for myasthenia gravis (MG), ocular MG, and Sjogren's disease.
- Vor completed enrollment of its phase three trial in MG and plans to start a phase three trial in ocular MG in the first half of 2027.
- The company is enrolling well in its phase three Sjogren's disease trial, which started in March 2026.
- Telitasisept modulates B cell development and inhibits pathogenic autoantibody production, with a two-to-one BAF to April mechanism, differentiating it from other BAF April inhibitors.
- Enrollment success in the MG trial was driven by strong KOL engagement and making the company accessible to clinical sites.
- Top-line data for the MG phase three trial is expected in the first half of 2027.
- Vor expects a preserved delta in MGADL scores in the MG trial, with a focus on breadth and durability of response.
- Safety data for MG is consistent with previous studies, showing minor infections but no increase in serious infections.
- The MG market in the US is currently around $3 billion and expected to reach $10 billion by the end of the decade.
- Vor sees a large unmet need in MG for therapies with deeper and more durable clinical efficacy than current treatments.
- Ocular MG is a logical adjacent indication with high unmet need and potential to prevent progression to generalized MG.
- Vor is engaging with regulators (FDA and EMA) and focusing on data quality and manufacturing for MG approval.
- Sjogren's disease is a B cell-driven autoimmune disease with both antibody-dependent and independent pathology, making Telitasisept's mechanism well suited.
- Vor's Sjogren's phase three trial is enrolling well, with experienced investigators and a design to overcome heterogeneity and placebo effects.
- Safety and tolerability in Sjogren's are expected to be consistent with prior data, with weekly injections being manageable for most patients.
- KOL feedback on Sjogren's is very positive, with interest in the drug's potential to address lymphoma risk and multiple disease domains.
- Vor is considering other indications but currently focused on completing three phase three studies in MG, ocular MG, and Sjogren's disease.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring